首頁 > 市場調查報告書 > 製藥

生物製劑基因治療學和RNAi

市場調查報告書

商品編碼

1891242

病毒載體及質粒DNA生產市場（第七版）－產業趨勢及全球預測（至2035年）－依企業規模、載體、應用、治療領域、製造商及地區劃分

Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Scale of Operation, Vector Manufactured, Application Area, Therapeutic Area, Manufacturer and Geographical Regions

出版日期: 2025年12月18日 | 出版商:

Roots Analysis | 英文 752 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

病毒載體與質粒DNA生產市場

預計全球病毒載體和質粒DNA生產市場在預測期內將以9.87%的複合年增長率增長，從目前的8.43億美元增長到2035年的21.61億美元。

病毒載體與質粒DNA生產市場

市場規模和機會分析基於以下參數進行細分：

企業規模

臨床前階段
臨床階段
商業化階段

應用領域

細胞療法
基因工程療法
疫苗

載體型別

腺相關病毒載體 (AAV)
腺病毒載體
慢病毒載體
逆轉錄病毒載體
非病毒載體
其他

治療領域

腫瘤學
罕見疾病
免疫系統疾病
神經系統疾病
感覺障礙
代謝性疾病
血液系統疾病
肌肉骨骼疾病
傳染病
眼科疾病
其他

生產商類型

內部生產商
合約生產商組織機構

地理區域

北美
歐洲
亞太地區
中東和北非
拉丁美洲

病毒載體與質粒DNA生產市場 - 成長與趨勢

病毒載體和非病毒載體已成為將遺傳物質遞送至目標細胞的重要工具，並構成了現代細胞和基因療法的基礎。近年來，全球約有30種基於病毒載體的療法獲得監管機構批准，目前美國有超過500種候選藥物正在進行臨床試驗。核准藥物數量的增加和持續的研究推動了對大規模病毒載體生產的需求。然而，該領域面臨許多挑戰，包括免疫原性風險和病毒載體分析的複雜性。為了應對這些挑戰，開發人員正越來越多地探索非病毒載體作為更安全、更易於規模化生產的選擇。

為了滿足日益增長的載體需求，業界正在推動各種製程改進。特別是，康寧生命科學公司開發了高密度細胞培養系統，例如 HYPERStack 和 CellSTACKs，利用透氣膜技術提高載體產量。該公司還引入了自動化系統，以簡化工作流程、減少人工勞動並縮短生產週期。這些技術創新正在為全球高效、可靠且經濟的載體生產奠定基礎。

根據病毒載體和質粒 DNA 生產市場報告，目前全球有 300 多家來自工業和非工業領域的公司正致力於支持不斷擴大的細胞療法、基因療法和基於載體的疫苗研發管線。投資、策略聯盟和設施擴建進一步推動了該行業的擴張，顯示各方堅定致力於應對生產挑戰。這些發展表明，病毒和非病毒載體的生產將迎來顯著增長，並成為即將到來的基因療法浪潮的重要組成部分。

病毒載體和質粒DNA生產市場 - 主要發現

本報告深入分析了全球病毒載體和質粒DNA生產市場的現狀，並指出了該行業的潛在成長機會。報告的主要發現包括：

目前，超過130家產業參與者聲稱具備生產各種類型病毒載體的必要能力，以滿足自身需求和/或合約服務安排。

在目前的市場格局中，約70%的病毒載體生產市場由合約製造商主導，其中約20%具備生產所有類型病毒載體的能力。
該產業約50%的公司具備在臨床前、臨床和商業化三個階段開展業務的能力。
我們繪製了世界各地不同載具製造商的設施分佈圖。尤其值得一提的是，歐洲已成為病毒和非病毒載體生產的主要中心。
約85%的非產業參與者從事AAV載體生產，另有80%專注於基因治療載體的生產。
大多數技術（43%）用於生產治療神經系統疾病的載體，其次是腫瘤治療（30%）。
目前，各參與者正在進行近150項擴建項目，凸顯了基於載體的細胞和基因治療領域日益增長的興趣和投資。
近期國內外利害關係人簽署的眾多合作協議也反映了該領域日益增長的利益。

為了提高效率並優化生產流程，預計多家載體和基因治療創新企業將與載體和基因治療生產商建立策略聯盟。
全球超過65%的基因治療和載體生產能力用於病毒載體生產，其中約55%的病毒載體生產能力位於北美。
鑑於目前有多種載體類型處於不同的研發階段，預計未來十年對這些載體的需求將顯著增長。
載體生產產業的整體市場機會預計將以9.87%的複合年增長率成長，且成長預計將廣泛分佈於不同規模的企業、載體類型和地理區域。

從長遠來看，基於載體的腫瘤療法（市場佔有率超過60%）預計將推動該市場的成長。

病毒載體和質粒DNA生產市場 - 主要細分市場

臨床細分市場在病毒載體和質粒DNA生產市場中佔最大的收入佔有率。

該市場依業務規模分為臨床前、臨床及商業化三個階段。對病毒載體和質粒DNA生產市場的分析表明，受眾多正在進行的基因和細胞療法臨床試驗的高需求驅動，臨床細分市場今年的市場佔有率更高（50%）。值得注意的是，商業化階段市場預計在預測期內將以13%的複合年增長率顯著成長。這主要得益於細胞和基因療法領域的進步，目前大多數療法都處於後期研發階段，預計將在近期進入市場。

慢病毒載體在病毒載體和質粒DNA生產市場中佔最大佔有率。

依載體類型劃分，整個市場包括AAV載體、腺病毒載體、慢病毒載體、逆轉錄病毒載體、非病毒載體和其他載體。今年，慢病毒載體佔了25%的顯著市場。目前，多種基於慢病毒載體的基因和細胞療法正處於後期臨床開發階段。此外，預計AAV載體的市佔率在預測期內也將顯著成長，複合年增長率將達到13%。這主要歸功於AAV載體的優勢，例如能夠高效轉導至多種細胞類型以及遞送大量DNA。

預計基因治療將佔病毒載體和質粒DNA生產市場的大部分佔有率。

依應用領域劃分，整個市場可分為細胞治療、基因治療和疫苗。目前，基因治療中使用的載體佔最大的市場佔有率（49%）。這主要歸因於核准用於多種適應症的基因療法數量不斷增加，顯著提高了對高品質載體生產的需求。此外，預計細胞治療中使用的載體佔有率將顯著增長，在預測期內複合年增長率將達到11%。這一趨勢主要受目前正在進行臨床試驗的療法數量不斷增加的推動。

腫瘤領域將佔病毒載體和質粒DNA生產市場最大的佔有率。

根據病毒載體和質粒DNA生產市場預測，受全球腫瘤疾病發生率上升的推動，今年基於載體的腫瘤疾病治療療法將佔最大的市場佔有率（47%）。此外，受核准用於眼科疾病的細胞和基因療法數量不斷增加的推動，預計基於載體的眼科疾病治療療法在預測期內將以31%的複合年增長率增長。

預期合約生產領域將主導病毒載體和質粒DNA生產市場。

此部分闡述了各類製造商（包括合約製造商和內部製造商）的市場分佈。目前，合約生產領域（57%）預計將主導市場，並在預測期內以更高的複合年增長率（11%）成長。這一趨勢歸因於合約生產組織 (CMO) 提供的可擴展性和靈活性，使其能夠快速響應不斷變化的生產需求並應對不斷增長的生產需求。

預計亞太地區和中東及北非地區將推動病毒載體和質粒 DNA 生產市場的成長。

目前，北美佔最大的市佔率 (54%)。這得歸功於該地區先進的醫療保健體系和研究環境。同時，亞太地區和中東及北非市場預計在預測期內將分別以 11% 的較高複合年增長率 (CAGR) 成長。這主要歸因於神經系統疾病治療需求的成長。這主要是由於慢性疾病（包括遺傳性疾病、罕見疾病和遺傳性疾病）的盛行率不斷上升，以及對高效先進療法的需求日益增長。

病毒載體和質粒DNA生產市場的主要參與者

Advanced BioScience Laboratories
AGC Biologics
Aldevron
Celonic
Catalent Biologics
Charles River Laboratories
Novartis
Oxford BioMedica

病毒載體和質粒DNA生產市場 - 研究範圍

市場規模和機會分析：本報告對病毒載體和質粒DNA生產市場進行了詳細分析，重點關注以下關鍵市場細分：[A] 企業規模，[B] 生產載體類型，[C] 應用領域，[D] 治療領域，[E] 生產商類型，以及 [F] 地理區域。市場情境 1：基於多個相關參數（例如 [A] 成立年份、[B] 公司規模、[C] 總部所在地、[D] 產品類型、[E] 生產設施所在地、[F] 製造商類型、[G] 業務規模、[H] 應用領域）對病毒載體和質粒 DNA 生產市場進行詳細評估。市場情境 2：基於多個相關參數（例如 [A] 成立年份、[B] 公司規模、[C] 總部所在地、[D] 產品類型、[E] 業務規模、[F] 應用領域）對參與質粒 DNA 和基因治療生產的行業參與者進行詳細評估。
市場情境 3：基於相關參數（例如 [A] 成立年份、[B] 載體生產設施所在地、[C] 製造商類型、[D] 業務規模、[E] 生產的載體類型、[F] 應用領域），對參與病毒載體、非病毒載體及其他新型載體和基因療法生產的非行業參與者進行詳細評估。
技術趨勢：基於 [A] 技術類型、[B] 技術目標、[C] 規模、[D] 載體類型和 [E] 應用領域，對該市場中各公司提供/開發的技術進行深入分析。
公司競爭力分析：對參與載體和基因療法生產的主要公司進行全面的競爭分析，考察 [A] 供應能力、[B] 生產能力和 [C] 服務能力等因素。
公司簡介：詳細介紹目前在北美、歐洲和亞太地區病毒載體和質粒DNA生產市場運營的主要公司，重點關注[A]成立年份、[B]總部所在地、[C]產品組合、[D]生產設施、[E]近期發展和[F]未來前景。
合作關係：深入分析基因治療、非病毒載體和病毒載體生產市場中已建立的合作關係，分析基於各種相關參數，例如[A]成立年份、[B]合作類型、[C]合作夥伴類型和[D]最活躍的參與者。
近期擴張：分析旨在增強公司在病毒和非病毒載體生產方面能力的近期擴張，分析基於多個參數，包括：[A]擴張年份、[B]擴張類型、[C]載體類型、[D]應用領域和[E]擴張的地理位置。
策略夥伴分析：基於多項參數（包括：[A] 開發人員實力，[B] 產品實力，[C] 載體類型，[D] 治療領域，以及 [E] 產品線實力）對載體和基因治療產品製造商（載體療法開發商與載體純化產品開發商）的潛在戰略合作夥伴進行深入分析。
新興載體：深入探討目前正在研究用於開發基因修飾療法的其他病毒和非病毒基因遞送方法的新興趨勢。
關鍵洞察：基於相關參數（載體類型、企業規模、製造商類型）、（載體類型和組織類型）以及（總部所在地和主要載體生產基地的地理位置）對質粒DNA和病毒載體製造領域的當前市場趨勢進行深入分析。
成本分析：分析可能影響載體定價的各種因素，並描述產品開發商/製造商在確定載體價格時可能採用的不同模型/方法。
可行性分析框架：該框架深入分析了病毒載體和非病毒載體生產商在決定是自行生產還是使用合約生產組織 (CMO) 的服務時應考慮的各種因素。
波特五力分析：對基因治療、非病毒載體和病毒載體生產市場中存在的五種競爭力量進行定性分析，包括：[A] 新進入者的威脅；[B] 藥物研發者的議價能力；[C] 載體和基因治療生產商的議價能力；[D] 替代技術的威脅能力；[C] 載體和基因治療生產商的議價能力；[D] 替代技術的威脅能力；以及 [E] 現有競爭對手之間的競爭壓力。
產能分析：基於公開資訊以及從一手和二手研究中獲得的見解，估算產業參與者載體生產設施的總裝置容量。該分析還涵蓋了依公司規模（小型、中型、大型）、總部所在地（依地區：北美、歐洲、亞太地區、世界其他地區）和生產設施所在地劃分的全球產能分佈。
需求分析：對病毒載體和非病毒載體的當前及未來需求進行詳細分析。該分析考慮了基於各種相關參數（例如[A]目標患者群體、[B]給藥頻率和[C]劑量強度）評估市售基因療法和基於載體的療法的臨床試驗。
市場影響分析：對可能影響基因療法、非病毒載體和病毒載體生產市場成長的因素進行詳細分析。該分析還包括對[A]關鍵驅動因素、[B]潛在限制因素、[C]新興機會和[D]現有挑戰的識別和分析。

Viral and non-viral vectors have become essential instruments for transferring genetic material into target cells, constituting the foundation of contemporary cell and gene therapies. In recent years,, approximately 30 therapies utilizing viral vectors have gained global regulatory approval, with more than 500 candidates currently in clinical trials in the US. The increase in approvals and continuing research has driven the need for extensive viral vector production. Nonetheless, this field encounters numerous challenges, such as risks of immunogenicity and the intricate character of viral vector analysis. To address these challenges, developers are progressively investigating the possibilities of non-viral vectors as more secure and scalable options.

To satisfy the increasing need for vectors, the sector has launched various process improvements. Interestingly, Corning Life Sciences has created high-density cell culture systems, such as HYPERStack and CellSTACKs, which utilize gas-permeable film technology to improve vector yields. The firm has additionally launched automation systems to enhance workflows, decrease manual involvement, and speed up production schedules. These advancements in technology have generated momentum for more efficient, reliable, and economical vector production globally.

Currently, more than 300 players from both industry and non-industry sectors worldwide are engaged in efforts to back the growing pipeline of cell therapies, gene therapies, and vector-based vaccines, according to the viral vectors and plasmid DNA manufacturing market report. The expansion in this sector is additionally driven by investments, strategic partnerships, and facility expansions, demonstrating a solid dedication to addressing production challenges. These advancements indicate that manufacturing for both viral and non-viral vectors is set for significant growth, positioning them as essential contributors to the upcoming wave of genetic therapies.

Viral Vector and Plasmid DNA Manufacturing Market: Key Insights

The report delves into the current state of the global viral vector and plasmid DNA manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, over 130 industry players claim to have the necessary capabilities to manufacture different types of viral vectors for in-house requirements and / or contract service engagements.

Viral Vector and Plasmid DNA Manufacturing Market - IMG1

The current viral vector manufacturing market landscape features the presence of around 70% contract manufacturers; among these, about 20% players have capability to manufacture all types of viral vectors.
Close to 50% of the companies in this domain have the capability to operate across all three scales of operation, namely preclinical, clinical and commercial.
We have mapped the locations of facilities established by different vector manufacturers worldwide; notably, Europe emerged as the prominent viral and non-viral vector manufacturing hub.
Around 85% of the non-industry players are engaged in the manufacturing of AAV vectors; further, close to 80% of the organizations are focused on manufacturing vectors for gene therapy applications.
Majority (43%) of the technologies are being utilized for manufacturing vectors that can be used for the treatment of neurological disorders, followed by oncological disorders (30%).
Presently, close to 150 expansions have been undertaken by various players, underscoring the growing interest and investment in the vector-based cell and gene therapy domain.
The rising interest in this domain is also reflected by the number of partnerships that have been inked in the recent past, involving both international and local stakeholders.

Viral Vector and Plasmid DNA Manufacturing Market - IMG2

In order to increase efficiency and optimize the manufacturing processes, several vector and gene therapy innovators are anticipated to forge strategic alliances with vector and gene therapy manufacturers.
Over 65% of the global installed gene therapy and vector manufacturing capacity is dedicated to viral vector manufacturing; ~55% of viral vector manufacturing capacity is installed in the facilities located in North America.
Given that there are several types of vectors being evaluated across various stages of development, the demand for such vectors is anticipated to rise significantly over the next decade.
The overall opportunity associated with vector manufacturing domain is anticipated to grow at the CAGR of 9.87%; it is likely to be well distributed across different, scales of operation, types of vectors and geographical regions.

Viral Vector and Plasmid DNA Manufacturing Market - IMG3

Over the long term, vector-based therapies for oncological disorders, which hold more than 60% market share are expected to drive the growth of this market.

Viral Vector and Plasmid DNA Manufacturing Market: Key Segments

Clinical Segment Occupies the Highest Revenue Share in the Viral Vector and Plasmid DNA Manufacturing Market

The market is segmented across various scales of operation such as preclinical, clinical and commercial. As per viral vector and plasmid DNA manufacturing market analysis, in the current year, the clinical segment occupies the higher market share (50%). This is a result of the high demand from numerous ongoing gene and cell therapy clinical trials. It is worth mentioning that the commercial stage segment is likely to witness a significant growth rate with a CAGR of 13% during the forecast period. This results from the advancing cell and gene therapy field, where the majority of therapies are in later development stages and are expected to enter the market in short-term.

Lentiviral Vector Segment Holds the Largest Viral Vector and Plasmid DNA Manufacturing Market Share

In terms of the type of vector manufactured, the overall market includes AAV vectors, adenoviral vectors, lentiviral vectors, retroviral vectors, non-viral vectors and other vectors. In the current year, lentiviral vector segment occupies the higher market share (25%). Several lentiviral vector based gene therapies and cell therapies are currently in the late stage of clinical development. Further, the market is likely to witness a substantial increase in the share of AAV vectors market share, growing at a CAGR of 13% during the forecast period. This is ascribed to advantages offered by AAV vectors, such as efficient transduction of various cell types and their ability to deliver large amounts of DNA.

Gene Therapy is Likely to Capture Majority of the Viral Vector and Plasmid DNA Manufacturing Market Share

Based on application area, the overall marker includes cell therapy, gene therapy and vaccine. Currently, vectors that are used in gene therapy segments occupy the highest market share (49%). This is due to the rising number of approved gene therapies for multiple indications, which has substantially increased the demand for high-quality vector production. Further, the market is likely to witness a substantial increase in the share of vectors that are used for cell therapy manufacturing, growing at a CAGR of 11% during the forecast period. This trend is due to an increasing number of therapies that are currently in clinical trials.

Oncological Disorders Segment Holds the Largest Viral Vector and Plasmid DNA Manufacturing Market Share

As per viral vector and plasmid DNA manufacturing market forecast, in the current year, vector-based therapies for the treatment of oncological disorders occupy the highest market share (47%), due to the growing incidence of such disorders across the globe. Further, vector-based therapies for the treatment of ophthalmic disorders are likely to grow at a CAGR of 31% during the forecast period. This is because of the growing number of approvals for cell and gene therapies for eye disorders.

Contract Manufacturing Segment is Likely to Dominate the Viral Vector and Plasmid DNA Manufacturing Market

This segment highlights the distribution of market across various types of manufacturers, such as contract manufacturing and in-house manufacturing. Currently, contract manufacturer segment (57%) is likely to dominate the market and is expected to grow at a higher CAGR (11%) during the forecast period. This trend arises from the ability of CMOs to provide scalability and flexibility, allowing them to quickly adjust to evolving manufacturing needs and handle increasing production demands.

Asia-Pacific and Middle East and North Africa is Likely to Propel the Growth of the Viral Vector and Plasmid DNA Manufacturing Market

Currently, North America (54%) captures the highest market share. This results from the developed healthcare system and research environment in North America. In contrast, the Asia-Pacific, and Middle East and North Africa markets are expected to expand at a comparatively higher CAGR of 11% each, during the forecast period. This is attributed to the growing prevalence of chronic conditions such as neurological conditions, genetic conditions, and rare illnesses and the heightened need for efficient and sophisticated treatments.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:

Chief Executive Officer, mid-sized company, Netherlands
Chief Executive Officer and Chief Scientific Officer, small company, Germany
Former Executive and Scientific Director, small company, Belgium
Co-Founder and President, mid-sized company, France
Former Director, Netherlands-based company
Director, Massachusetts-based organization
Former Scientific Director, France-based organization
Former Managing Director, small company, Japan
Scientific Director, small company, US
Key Account Management, mid-sized company, Germany
Head of Project Management, small company, Germany
Director of Business Development, small company, US
ATMP Key Account Manager, France-based organization
Chief Scientific Officer, small company, France
Director of Marketing and Technical Support, mid-sized company, France
Head of Communications, mid-sized company, Spain
Independent Consultant

Example Players in the Viral Vector and Plasmid DNA Manufacturing Market

Advanced BioScience Laboratories
AGC Biologics
Aldevron
Celonic
Catalent Biologics
Charles River Laboratories
Novartis
Oxford BioMedica

Viral Vector and Plasmid DNA Manufacturing Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the viral vector and plasmid DNA manufacturing market, focusing on key market segments, including [A] scale of operation, [B] type of vector manufactured, [C] application area, [D] therapeutic area, [E] type of manufacturer and [F] geographical regions.
Market Landscape 1: A detailed assessment of the viral vector and plasmid DNA manufacturing market based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of product manufactured, [E] location of manufacturing facility, [F] type of manufacturer, [G] scale of operation, and [H] application area.
Market Landscape 2: A detailed assessment of the industry players engaged in manufacturing plasmid DNA and gene therapies based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of product manufactured, [E] scale of operation, and [F] application area.
Market Landscape 3: A detailed assessment of the non-industry players engaged in the manufacturing of viral, non viral and other novel types of vectors and gene therapies, based on relevant parameters such as [A] year of establishment, [B] location of vector manufacturing facility, [C] type of manufacturer, [D] scale of operation, [E] type of vector manufactured and [F] application area.
Technology Landscape: An in-depth analysis of the technologies offered / developed by the companies engaged in this market, based on the [A] type of technology, [B] purpose of technology, [C] scale of, [D] type of vector, and [E] application area.
Company Competitiveness Analysis: A comprehensive competitive analysis of key players engaged in manufacturing vectors and gene therapies, examining factors, such as [A] supplier strength [B] manufacturing strength and [C] service strength.
Company Profiles: In-depth profiles of prominent players based in regions, namely North America, Europe and Asia-Pacific that are currently involved in the viral vector and plasmid DNA manufacturing market, focusing on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] manufacturing facilities, [E] recent developments and [F] an informed future outlook.
Partnerships and Collaborations An insightful analysis of the partnerships and collaborations established in gene therapy, non viral vector and viral vector manufacturing market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
Recent Expansions: An analysis of the recent expansions undertaken by various companies in order to augment their respective capabilities related to viral vector and non viral vector manufacturing, based on several parameters, such as [A] year of expansion, [B] type of expansion, [C] type of vector, [D] application area and [E] geographical location of the expansion.
Strategic Partner Analysis: An insightful analysis evaluating the potential strategic partners (comparing vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as [A] developer strength, [B] product strength, [C] type of vector, [D] therapeutic area and [E] pipeline strength.
Emerging Vectors: An elaborate discussion on the emerging trends of other viral / non viral gene delivery approaches that are currently in research for the development of therapies involving genetic modification.
Key Insights: An insightful analysis, highlighting the contemporary market trends in the plasmid DNA and viral vector manufacturing domain, based on relevant parameters, such as (type of vector, scale of operation and type of manufacturer), (type of vector and type of organization) and (location of headquarters and geographical location of key vector manufacturing hubs).
Cost Price Analysis: An analysis of various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of their proprietary vectors.
Go / No-Go Framework Analysis: An insightful go / no-go framework analysis, highlighting various factors that needs to be considered by viral vector and non viral vector manufacturing companies while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
Porter's Five Forces Analysis: A qualitative analysis, highlighting the five competitive forces prevalent in gene therapy, non viral vector and viral vector manufacturing market, including [A] threats for new entrants, [B] bargaining power of drug developers, [C] bargaining power of vector and gene therapy manufacturers, [D] threats of substitute technologies and [E] rivalry among existing competitors.
Capacity Analysis: An estimate of the overall, installed vector manufacturing capacity of industry players based on the information available in the public domain, and insights generated from both secondary and primary research. The analysis also highlights the distribution of global capacity by company size (small, mid-sized and large), location of headquarters (region) (North America, Europe, Asia Pacific and the rest of the world) and location of manufacturing facility.
Demand Analysis: An in-depth analysis to estimate the current and future demand for viral vectors and non viral vectors, taking into consideration the marketed gene therapies and clinical studies evaluating vector-based therapies, based on various relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength.
Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of gene therapy, non viral vector and viral vector manufacturing market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What is the current global capacity of developers?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Key Questions Answered
1.5. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Viral and Non-Viral Gene Transfer Techniques
6.3. Viral Vectors Used in Genetically Modified Therapies
6.4. Types of Viral Vectors
- 6.4.1. Adeno-associated Viral Vectors
  - 6.4.1.1. Overview
  - 6.4.1.2. Design and Manufacturing
  - 6.4.1.3. Advantages
  - 6.4.1.4. Limitations
- 6.4.2. Adenoviral Vectors
  - 6.4.2.1. Overview
  - 6.4.2.2. Design and Manufacturing
  - 6.4.2.3. Advantages
  - 6.4.2.4. Limitations
- 6.4.3. Lentiviral Vectors
  - 6.4.3.1. Overview
  - 6.4.3.2. Design and Manufacturing
  - 6.4.3.3. Advantages
  - 6.4.3.4. Limitations
- 6.4.4. Retroviral Vectors
  - 6.4.4.1. Overview
  - 6.4.4.2. Design and Manufacturing
  - 6.4.4.3. Advantages
  - 6.4.4.4. Limitations
- 6.4.5. Other Viral Vectors
  - 6.4.5.1. Alphavirus
  - 6.4.5.2. Foamy Virus
  - 6.4.5.3. Herpes Simplex Virus
  - 6.4.5.4. Sendai Virus
  - 6.4.5.5. Simian Virus
  - 6.4.5.6. Vaccinia Virus
  - 6.4.5.7. Chimeric Viral Vectors
6.5. Types of Non-Viral Vectors
- 6.5.1. Plasmid DNA
- 6.5.2. Liposomes, Lipoplexes and Polyplexes
- 6.5.3. Oligonucleotides
- 6.5.4. Other Non-Viral Vectors
6.6. Gene Delivery using Non-Viral Vectors
- 6.6.1. Biolistic Methods
- 6.6.2. Electroporation
- 6.6.3. Receptor Mediated Gene Delivery
- 6.6.4. Gene Activated Matrix (GAM)
6.7. Applications of Viral and Non-Viral Vectors
- 6.7.1. Cell and Gene Therapy
- 6.7.2. Vaccine
6.8. Current / Ongoing Trends in Vector Development / Manufacturing
- 6.8.1. Vector Engineering
- 6.8.2. Cargo Engineering
6.9. Vector Manufacturing
- 6.9.1. Types of Vector Manufacturers
- 6.9.2. Viral Vector Manufacturing Processes
  - 6.9.2.1. Vector Production
  - 6.9.2.2. Adherent and Suspension Cultures
  - 6.9.2.3. Unit Process Versus Multiple Parallel Processes
  - 6.9.2.4. Cell Culture Systems for Production of Viral Vectors
    - 6.9.2.4.1. Small Scale / Laboratory Scale Cell Culture Systems
    - 6.9.2.4.2. Large Scale Cell Culture Systems
      - 6.9.2.4.2.1. Stirred Tank Reactor Systems
      - 6.9.2.4.2.2. Fixed Bed Reactors / Packed Bed Reactors
      - 6.9.2.4.2.3. Wave Bioreactor Systems
  - 6.9.2.5. Serum-Containing versus Serum-Free Media
- 6.9.3. Bioprocessing of Viral Vectors
  - 6.9.3.1. AAV Vector Production
  - 6.9.3.2. Adenoviral Vector Production
  - 6.9.3.3. Lentiviral Vector Production
  - 6.9.3.4. Y -Retroviral Vector Production
- 6.9.4. Key Challenges Associated with Vector Manufacturing
6.10. Future Perspectives

7. VIRAL VECTOR MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters
- 7.2.4. Analysis by Type of Product Manufactured
- 7.2.5. Analysis by Type of Manufacturer
- 7.2.6. Analysis by Scale of Operation
- 7.2.7. Analysis by Type of Viral Vector Manufactured
- 7.2.8. Analysis by Application Area

8. PLASMID DNA MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
- 8.2.1. Analysis by Year of Establishment
- 8.2.2. Analysis by Company Size
- 8.2.3. Analysis by Location of Headquarters
- 8.2.4. Analysis by Type of Company
- 8.2.5. Analysis by Type of Venture
- 8.2.6. Analysis by Type of Services Offered
- 8.2.7. Analysis by Type of Plasmid DNA Manufactured
- 8.2.8. Analysis by Grade of Plasmid DNA Manufactured
- 8.2.9. Analysis by Cell Bank
- 8.2.10. Analysis by Scale of Operation
- 8.2.11. Analysis by Application Area
- 8.2.12. Analysis by Viral Vector Used
- 8.2.13. Analysis by Type of Vaccine Developed
- 8.2.14. Analysis by Number of Facilities

9. VIRAL VECTOR AND PLASMID DNA MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

9.1. Chapter Overview
9.2. Viral Vector and Plasmid DNA Manufacturers (Non-Industry Players): Overall Market Landscape
- 9.2.1. Analysis by Year of Establishment
- 9.2.2. Analysis by Company Size
- 9.2.3. Analysis by Location of Headquarters
- 9.2.4. Analysis by Type of Vector
- 9.2.5. Analysis by Scale of Operation
- 9.2.6. Analysis by Type of Manufacturer
- 9.2.7. Analysis by Application Area

10. VECTOR MANUFACTURING TECHNOLOGIES LANDSCAPE

10.1. Chapter Overview
10.2. Vector Manufacturing Technologies: Overall Market Landscape
- 10.2.1. Analysis by Type of Technology
- 10.2.2. Analysis by Purpose of Technology
- 10.2.3. Analysis by Scale of Operation
- 10.2.4. Analysis by Type of Vector
- 10.2.5. Analysis by Application Area
- 10.2.6. Most Active Players: Analysis by Number of Technologies

11. COMPANY COOMPETITIVENESS ANALYSIS

11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Viral Vector Manufacturers: Company Competitiveness Analysis
- 11.3.1. Players based in North America
- 11.3.2. Players based in Europe
- 11.3.3. Players based in Asia-Pacific and Rest of the World
11.4. Plasmid DNA Manufacturers: Company Competitiveness Analysis
- 11.4.1. Players based in North America
- 11.4.2. Players based in Europe
- 11.4.3. Players based in Asia-Pacific and Rest of the World

12. VECTOR MANUFACTURERS BASED IN NORTH AMERICA

12.1. Chapter Overview
12.2. Key Players
- 12.2.1. Advanced BioScience Laboratories
  - 12.2.1.1. Company Overview
  - 12.2.1.2. Vector Manufacturing Portfolio
  - 12.2.1.3. Recent Developments and Future Outlook
- 12.2.2. Catalent Biologics
  - 12.2.2.1. Company Overview
  - 12.2.2.2. Financial Information
  - 12.2.2.3. Vector Manufacturing Portfolio
  - 12.2.2.4. Recent Developments and Future Outlook
- 12.2.3. Charles River Laboratories
  - 12.2.3.1. Company Overview
  - 12.2.3.2. Financial Information
  - 12.2.3.3. Vector Manufacturing Portfolio
  - 12.2.3.4. Recent Developments and Future Outlook
- 12.2.4. Thermo Fisher Scientific
  - 12.2.4.1. Company Overview
  - 12.2.4.2. Financial Information
  - 12.2.4.3. Vector Manufacturing Portfolio
  - 12.2.4.4. Recent Development and Future Outlook
- 12.2.5. VectorBuilder
  - 12.2.5.1. Company Overview
  - 12.2.5.2. Financial Information
  - 12.2.5.3. Vector Manufacturing Portfolio
  - 12.2.5.4. Recent Developments and Future Outlook
12.3. Other Key Players
- 12.3.1. AGC Biologics
  - 12.3.1.1. Company Overview
  - 12.3.1.2. Vector Manufacturing Portfolio
- 12.3.2. Aldevron
  - 12.3.2.1. Company Overview
  - 12.3.2.2. Vector Manufacturing Portfolio
- 12.3.3. Matica Biotechnology
  - 12.3.3.1. Company Overview
  - 12.3.3.2. Vector Manufacturing Portfolio
- 12.3.4. Resilience
  - 12.3.4.1. Company Overview
  - 12.3.4.2. Vector Manufacturing Portfolio

13. VECTOR MANUFACTURERS BASED IN EUROPE

13.1. Chapter Overview
13.2. Key Players
- 13.2.1. Lonza
  - 13.2.1.1. Company Overview
  - 13.2.1.2. Financial Information
  - 13.2.1.3. Vector Manufacturing Portfolio
  - 13.2.1.4. Recent Developments and Future Outlook
- 13.2.2. Touchlight
  - 13.2.2.1. Company Overview
  - 13.2.2.2. Vector Manufacturing Portfolio
  - 13.2.2.3. Recent Developments and Future Outlook
13.3. Other Key Players
- 13.3.1. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
  - 13.3.1.1. Company Overview
  - 13.3.1.2. Vector Manufacturing Portfolio
- 13.3.2. Biovian
  - 13.3.2.1. Company Overview
  - 13.3.2.2. Vector Manufacturing Portfolio
- 13.3.3. Celonic
  - 13.3.3.1. Company Overview
  - 13.3.3.2. Vector Manufacturing Portfolio
- 13.3.4. Centre for Process Innovation
  - 13.3.4.1. Company Overview
  - 13.3.4.2. Vector Manufacturing Portfolio
- 13.3.5. CEVEC Pharmaceuticals
  - 13.3.5.1. Company Overview
  - 13.3.5.2. Vector Manufacturing Portfolio
- 13.3.6. NorthX Biologics
  - 13.3.6.1. Company Overview
  - 13.3.6.2. Vector Manufacturing Portfolio
- 13.3.7. Novartis
  - 13.3.7.1. Company Overview
  - 13.3.7.2. Vector Manufacturing Portfolio
- 13.3.8. Oxford BioMedica
  - 13.3.8.1. Company Overview
  - 13.3.8.2. Vector Manufacturing Portfolio
- 13.3.9. Sanofi
  - 13.3.9.1. Company Overview
  - 13.3.9.2. Vector Manufacturing Portfolio

14. VECTOR MANUFACTURERS BASED IN ASIA-PACIFIC

15. VECTOR MANUFACTURERS IN ASIA-PACIFIC

15.1. Chapter Overview
15.2. Key Players
- 15.2.1. CoJourney
  - 15.2.1.1. Company Overview
  - 15.2.1.2. Vector Manufacturing Portfolio
  - 15.2.1.3. Recent Developments and Future Outlook
- 15.2.2. Esco Aster
  - 15.2.2.1. Company Overview
  - 15.2.2.2. Vector Manufacturing Portfolio
  - 15.2.2.3. Recent Developments and Future Outlook
- 15.2.3. Wuxi AppTec
  - 15.2.3.1. Company Overview
  - 15.2.3.2. Financial Information
  - 15.2.3.3. Vector Manufacturing Portfolio
  - 15.2.3.4. Recent Developments and Future Outlook
15.3. Other Key Players
- 15.3.1. Altruist Biotechnology
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Vector Manufacturing Portfolio
- 15.3.2. Jiangsu Puxin Biopharmaceutical
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Vector Manufacturing Portfolio
- 15.3.3. Nikon CeLL innovation
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Vector Manufacturing Portfolio

16. PORTER'S FIVE FORCES ANALYSIS

16.1. Chapter Overview
16.2. Methodology and Assumptions
16.3. Key Parameters
- 16.3.1. Threats of New Entrants
- 16.3.2. Bargaining Power of Suppliers
- 16.3.3. Bargaining Power of Buyers
- 16.3.4. Threats of Substitute Products
- 16.3.5. Rivalry Among Existing Competitors
16.4. Concluding Remarks

17. PARTNERSHIPS AND COLLAORATIONS

17.1. Chapter Overview
17.2. Partnership Models
17.3. Vector Manufacturing: Partnerships and Collaborations
- 17.3.1. Analysis by Year of Partnership
- 17.3.2. Analysis by Type of Partnership
- 17.3.3. Analysis by Scale of Operation
- 17.3.4. Analysis by Type of Vector Manufactured
- 17.3.5. Analysis by Therapeutic Area
- 17.3.6. Analysis by Application Area
- 17.3.7. Most Active Players: Analysis by Number of Partnerships
- 17.3.8. Analysis by Geography
  - 17.3.8.1. Local and International Agreements
  - 17.3.8.2. Intercontinental and Intracontinental Agreements

18. RECENT EXPANSIONS

18.1. Chapter Overview
18.2. Type of Expansions
18.3. Vector Manufacturing: Recent Expansions
- 18.3.1. Analysis by Year of Expansion
- 18.3.2. Analysis by Type of Expansion
- 18.3.3. Analysis by Year and Type of Expansion
- 18.3.4. Most Active Players: Analysis by Number of Expansions
- 18.3.5. Most Active Players: Analysis by Amount Invested
- 18.3.6. Analysis by Type of Manufacturing Facility
- 18.3.7. Analysis by Scale of Operation
- 18.3.8. Analysis by Type of Vector Manufactured
- 18.3.9. Analysis by Application Area
- 18.3.10. Analysis by Geography
  - 18.3.10.1. Intercontinental and Intracontinental Expansions
  - 18.3.10.2. Analysis by Location of Expansion

19. STRATEGIC PARTNER ANAYSIS

19.1. Chapter Overview
19.2. Methodology and Key Parameters
19.3. Strategic Partner Analysis: Viral Vector based Therapy Developers
- 19.3.1. Opportunity for AAV Vector based Therapy Developers
  - 19.3.1.1. Most Likely Partners
  - 19.3.1.2. Likely Partners
  - 19.3.1.3. Less Likely Partners
  - 19.3.1.4. Least Likely Partners
- 19.3.2. Opportunity for Adenoviral Vector based Therapy Developers
  - 19.3.2.1. Most Likely Partners
  - 19.3.2.2. Likely Partners
  - 19.3.2.3. Less Likely Partners
  - 19.3.2.4. Least Likely Partners
- 19.3.3. Opportunity for Lentiviral Vector based Therapy Developers
  - 19.3.3.1. Most Likely Partners
  - 19.3.3.2. Likely Partners
  - 19.3.3.3. Less Likely Partners
  - 19.3.3.4. Least Likely Partners
- 19.3.4. Opportunity for Retroviral Vector based Therapy Developers
  - 19.3.4.1. Most Likely Partners
  - 19.3.4.2. Likely Partners
  - 19.3.4.3. Less Likely Partners
  - 19.3.4.4. Least Likely Partners
- 19.3.5. Opportunity for Other Viral Vector based Therapy Developers
  - 19.3.5.1. Most Likely Partners
  - 19.3.5.2. Likely Partners
  - 19.3.5.3. Less Likely Partners
  - 19.3.5.4. Least Likely Partners

20. EMERGING VECTORS

20.1. Chapter Overview
- 20.1.1. Alphavirus based Vectors
- 20.1.2. Anc80 based Vectors
- 20.1.3. Bifidobacterium longum based Vectors
- 20.1.4. Cytomegalovirus based Vectors
- 20.1.5. Listeria monocytogenes based Vectors
- 20.1.6. Minicircle DNA based Vectors
- 20.1.7. Myxoma Virus based Vectors
- 20.1.8. Self-Complementary Vectors
- 20.1.9. Sendai Virus based Vectors
- 20.1.10. Sleeping Beauty Transposons
- 20.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors
- 20.1.12. Chimeric Viral Vectors

21. KEY INSIGHTS

21.1. Chapter Overview
21.2. Vector and Gene Therapy Manufacturers: Key Insights
- 21.2.1. Analysis by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
- 21.2.2. Analysis by Type of Vector Manufactured and Company Size
- 21.2.3. Analysis by Type of Organization and Geography
  - 21.2.3.1. Contract Manufacturing Organizations
  - 21.2.3.2. In-House Manufacturers
  - 21.2.3.3. In-House and Contract Manufacturing Organizations
- 21.2.4. Analysis by Type of Vector Manufactured and Location of Headquarters
  - 21.2.4.1. AAV Vector Manufacturers
  - 21.2.4.2. Adenoviral Vector Manufacturers
  - 21.2.4.3. Lentiviral Vector Manufacturers
  - 21.2.4.4. Retroviral Vector Manufacturers
  - 21.2.4.5. Plasmid DNA Manufacturers

22. COST PRICE ANALYSIS

22.1. Chapter Overview
22.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
22.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models
- 22.3.1. Pricing Models Based on Expert Opinions
- 22.3.2. Pricing Models Based on Manufacturing Cost
  - 22.3.2.1. Pricing Models Based on Technology Used
  - 22.3.2.2. Pricing Models Based on Scale of Operation
  - 22.3.2.3. Pricing Models Based on Type of Client
- 22.3.3. Prices of Different Types of Vectors
22.4. Concluding Remarks

23. OUTSOURCING: GO / NO-GO FRAMEWORK

23.1. Chapter Overview
23.2. Outsourcing: Go / No-Go Framework
23.3. Vector Manufacturing Outsourcing: Go / No-Go Framework
- 23.3.1. Key Parameters and Assumptions
- 23.3.2. Methodology
- 23.3.3. Results and Interpretations
  - 23.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
  - 23.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
  - 23.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies

24. CAPACITY ANALYSIS

24.1. Chapter Overview
24.2. Methodology and Key Assumptions
24.3. Viral Vector and Plasmid DNA Manufacturing: Global Installed Capacity
24.4. Viral Vector Manufacturing: Global Installed Capacity
- 24.4.1. Analysis by Company Size
- 24.4.2. Analysis by Scale of Operation
- 24.4.3. Analysis by Location of Headquarters (Region)
- 24.4.4. Analysis by Location of Manufacturing Facility
24.5. Plasmid DNA Manufacturing: Global Installed Capacity
- 24.5.1. Analysis by Company Size
- 24.5.2. Analysis by Scale of Operation
- 24.5.3. Analysis by Location of Headquarters (Region)
- 24.5.4. Analysis by Location of Manufacturing Facility

25. DEMAND ANALYSIS

25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Global Demand for Viral Vectors and Plasmid DNA, Till 2035
25.4. Global Clinical Demand for Viral Vectors and Plasmid DNA, Till 2035
- 25.4.1. Analysis by Type of Vector
- 25.4.2. Analysis by Type of Therapy
- 25.4.3. Analysis by Therapeutic Area
- 25.4.4. Analysis by Geography
25.5. Global Commercial Demand for Viral Vectors and Plasmid DNA, Till 2035
- 25.5.1. Analysis by Type of Vector
- 25.5.2. Analysis by Type of Therapy
- 25.5.3. Analysis by Therapeutic Area
- 25.5.4. Analysis by Geography
25.6. Demand and Supply Analysis

26. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

26.1. Chapter Overview
26.2. Market Drivers
26.3. Market Restraints
26.4. Market Opportunities
26.5. Market Challenges

27. GLOBAL VECTOR MANUFACTURING MARKET

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Global Vector Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 27.3.1. Scenario Analysis
  - 27.3.1.1. Conservative Scenario
  - 27.3.1.2. Optimistic Scenario
27.4. Key Market Segmentations

28. VECTOR MANUFACTURING MARKET, BY SCALE OF OPERATION

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Vector Manufacturing Market: Distribution by Scale of Operation
- 28.3.1. Preclinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 28.3.2. Clinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 28.3.3. Commercial Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.4. Data Triangulation and Validation

29. VECTOR MANUFACTURING MARKET, BY TYPE OF VECTOR MANUFACTURED

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Vector Manufacturing Market: Distribution by Type of Vector
- 29.3.1. AAV Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.3.2. Adenoviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.3.3. Lentiviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.3.4. Retroviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.3.5. Non-Viral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.3.6. Other Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.4. Data Triangulation and Validation

30. VECTOR MANUFACTURING MARKET, BY APPLICATION AREA

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Vector Manufacturing Market: Distribution by Application Area
- 30.3.1. Cell Therapy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 30.3.2. Gene Therapy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 30.3.3. Vaccines: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4. Data Triangulation and Validation

31. VECTOR MANUFACTURING MARKET, BY THERAPEUTIC AREA

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Vector Manufacturing Market: Distribution by Therapeutic Area
- 31.3.1. Oncological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.2. Rare Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.3. Immunological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.4. Neurological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.5. Sensory Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.6. Metabolic Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.7. Blood Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.8. Musculoskeletal Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.9. Infectious Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.10. Ophthalmic Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.11. Other Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4. Data Triangulation and Validation

32. VECTOR MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Vector Manufacturing Market: Distribution by Type of Manufacturer
- 32.3.1. In-house Manufacturers: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 32.3.2. Contract Manufacturing Organizations: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.4. Data Triangulation and Validation

33. VECTOR MANUFACTURING MARKET, BY GEOGRAPHICAL REGION

33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Vector Manufacturing Market: Distribution by Geographical Region
- 33.3.1. North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 33.3.2. Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 33.3.3. Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 33.3.4. Middle East and North Africa: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 33.3.5. Latin America and Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4. Data Triangulation and Validation

34. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

34.1. Vector Manufacturing Market in North America: Distribution by Scale of Operation
- 34.1.1. Vector Manufacturing Market in North America for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.1.2. Vector Manufacturing Market in North America for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.1.3. Vector Manufacturing Market in North America for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.2. Vector Manufacturing Market in North America: Distribution by Type of Vector Manufactured
- 34.2.1. Vector Manufacturing Market in North America for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.2.2. Vector Manufacturing Market in North America for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.2.3. Vector Manufacturing Market in North America for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.2.4. Vector Manufacturing Market in North America for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.2.5. Vector Manufacturing Market in North America for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.2.6. Vector Manufacturing Market in North America for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.3. Vector Manufacturing Market in North America: Distribution by Application Area
- 34.3.1. Vector Manufacturing Market in North America for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.3.2. Vector Manufacturing Market in North America for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.3.3. Vector Manufacturing Market in North America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4. Vector Manufacturing Market in North America: Distribution by Therapeutic Area
- 34.4.1. Vector Manufacturing Market in North America for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.2. Vector Manufacturing Market in North America for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.3. Vector Manufacturing Market in North America for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.4. Vector Manufacturing Market in North America for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.5. Vector Manufacturing Market in North America for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.6. Vector Manufacturing Market in North America for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.7. Vector Manufacturing Market in North America for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.8. Vector Manufacturing Market in North America for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.9. Vector Manufacturing Market in North America for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.10. Vector Manufacturing Market in North America for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.4.11. Vector Manufacturing Market in North America for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.5. Vector Manufacturing Market in North America: Distribution by Type of Manufacturer
- 34.5.1. Vector Manufacturing Market in North America for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 34.5.2. Vector Manufacturing Market in North America for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

35. MARKET OPPORTUNITY ANALYSIS: EUROPE

35.1. Vector Manufacturing Market in Europe: Distribution by Scale of Operation
- 35.1.1. Vector Manufacturing Market in Europe for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.1.2. Vector Manufacturing Market in Europe for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.1.3. Vector Manufacturing Market in Europe for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
35.2. Vector Manufacturing Market in Europe: Distribution by Type of Vector Manufactured
- 35.2.1. Vector Manufacturing Market in Europe for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.2.2. Vector Manufacturing Market in Europe for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.2.3. Vector Manufacturing Market in Europe for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.2.4. Vector Manufacturing Market in Europe for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.2.5. Vector Manufacturing Market in Europe for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.2.6. Vector Manufacturing Market in Europe for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
35.3. Vector Manufacturing Market in Europe: Distribution by Application Area
- 35.3.1. Vector Manufacturing Market in Europe for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.3.2. Vector Manufacturing Market in Europe for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.3.3. Vector Manufacturing Market in Europe for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
35.4. Vector Manufacturing Market in Europe: Distribution by Therapeutic Area
- 35.4.1. Vector Manufacturing Market in Europe for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.2. Vector Manufacturing Market in Europe for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.3. Vector Manufacturing Market in Europe for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.4. Vector Manufacturing Market in Europe for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.5. Vector Manufacturing Market in Europe for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.6. Vector Manufacturing Market in Europe for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.7. Vector Manufacturing Market in Europe for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.8. Vector Manufacturing Market in Europe for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.9. Vector Manufacturing Market in Europe for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.10. Vector Manufacturing Market in Europe for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.4.11. Vector Manufacturing Market in Europe for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
35.5. Vector Manufacturing Market in Europe: Distribution by Type of Manufacturer
- 35.5.1. Vector Manufacturing Market in Europe for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 35.5.2. Vector Manufacturing Market in Europe for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

36. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

36.1. Vector Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
- 36.1.1. Vector Manufacturing Market in Asia-Pacific for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.1.2. Vector Manufacturing Market in Asia-Pacific for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.1.3. Vector Manufacturing Market in Asia-Pacific for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.2. Vector Manufacturing Market in Asia-Pacific: Distribution by Type of Vector Manufactured
- 36.2.1. Vector Manufacturing Market in Asia-Pacific for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.2.2. Vector Manufacturing Market in Asia-Pacific for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.2.3. Vector Manufacturing Market in Asia-Pacific for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.2.4. Vector Manufacturing Market in Asia-Pacific for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.2.5. Vector Manufacturing Market in Asia-Pacific for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.2.6. Vector Manufacturing Market in Asia-Pacific for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.3. Vector Manufacturing Market in Asia-Pacific: Distribution by Application Area
- 36.3.1. Vector Manufacturing Market in Asia-Pacific for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.3.2. Vector Manufacturing Market in Asia-Pacific for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.3.3. Vector Manufacturing Market in Asia-Pacific for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4. Vector Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
- 36.4.1. Vector Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.2. Vector Manufacturing Market in Asia-Pacific for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.3. Vector Manufacturing Market in Asia-Pacific for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.4. Vector Manufacturing Market in Asia-Pacific for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.5. Vector Manufacturing Market in Asia-Pacific for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.6. Vector Manufacturing Market in Asia-Pacific for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.7. Vector Manufacturing Market in Asia-Pacific for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.8. Vector Manufacturing Market in Asia-Pacific for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.9. Vector Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.10. Vector Manufacturing Market in Asia-Pacific for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.4.11. Vector Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.5. Vector Manufacturing Market in Asia-Pacific: Distribution by Type of Manufacturer
- 36.5.1. Vector Manufacturing Market in Asia-Pacific for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 36.5.2. Vector Manufacturing Market in Asia-Pacific for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

37. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

37.1. Vector Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation
- 37.1.1. Vector Manufacturing Market in Middle East and North Africa for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.1.2. Vector Manufacturing Market in Middle East and North Africa for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.1.3. Vector Manufacturing Market in Middle East and North Africa for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.2. Vector Manufacturing Market in Middle East and North Africa: Distribution by Type of Vector Manufactured
- 37.2.1. Vector Manufacturing Market in Middle East and North Africa for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.2.2. Vector Manufacturing Market in Middle East and North Africa for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.2.3. Vector Manufacturing Market in Middle East and North Africa for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.2.4. Vector Manufacturing Market in Middle East and North Africa for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.2.5. Vector Manufacturing Market in Middle East and North Africa for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.2.6. Vector Manufacturing Market in Middle East and North Africa for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.3. Vector Manufacturing Market in Middle East and North Africa: Distribution by Application Area
- 37.3.1. Vector Manufacturing Market in Middle East and North Africa for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.3.2. Vector Manufacturing Market in Middle East and North Africa for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.3.3. Vector Manufacturing Market in Middle East and North Africa for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4. Vector Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area
- 37.4.1. Vector Manufacturing Market in Middle East and North Africa for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.2. Vector Manufacturing Market in Middle East and North Africa for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.3. Vector Manufacturing Market in Middle East and North Africa for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.4. Vector Manufacturing Market in Middle East and North Africa for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.5. Vector Manufacturing Market in Middle East and North Africa for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.6. Vector Manufacturing Market in Middle East and North Africa for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.7. Vector Manufacturing Market in Middle East and North Africa for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.8. Vector Manufacturing Market in Middle East and North Africa for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.9. Vector Manufacturing Market in Middle East and North Africa for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.10. Vector Manufacturing Market in Middle East and North Africa for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.4.11. Vector Manufacturing Market in Middle East and North Africa for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.5. Vector Manufacturing Market in Middle East and North Africa: Distribution by Type of Manufacturer
- 37.5.1. Vector Manufacturing Market in Middle East and North Africa for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 37.5.2. Vector Manufacturing Market in Middle East and North Africa for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

38. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

38.1. Vector Manufacturing Market in Latin America: Distribution by Scale of Operation
- 38.1.1. Vector Manufacturing Market in Latin America for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.1.2. Vector Manufacturing Market in Latin America for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.1.3. Vector Manufacturing Market in Latin America for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.2. Vector Manufacturing Market in Latin America: Distribution by Type of Vector Manufactured
- 38.2.1. Vector Manufacturing Market in Latin America for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.2.2. Vector Manufacturing Market in Latin America for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.2.3. Vector Manufacturing Market in Latin America for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.2.4. Vector Manufacturing Market in Latin America for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.2.5. Vector Manufacturing Market in Latin America for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.2.6. Vector Manufacturing Market in Latin America for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.3. Vector Manufacturing Market in Latin America: Distribution by Application Area
- 38.3.1. Vector Manufacturing Market in Latin America for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.3.2. Vector Manufacturing Market in Latin America for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.3.3. Vector Manufacturing Market in Latin America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4. Vector Manufacturing Market in Latin America: Distribution by Therapeutic Area
- 38.4.1. Vector Manufacturing Market in Latin America for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.2. Vector Manufacturing Market in Latin America for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.3. Vector Manufacturing Market in Latin America for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.4. Vector Manufacturing Market in Latin America for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.5. Vector Manufacturing Market in Latin America for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.6. Vector Manufacturing Market in Latin America for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.7. Vector Manufacturing Market in Latin America for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.8. Vector Manufacturing Market in Latin America for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.9. Vector Manufacturing Market in Latin America for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.10. Vector Manufacturing Market in Latin America for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.4.11. Vector Manufacturing Market in Latin America for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.5. Vector Manufacturing Market in Latin America: Distribution by Type of Manufacturer
- 38.5.1. Vector Manufacturing Market in Latin America for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 38.5.2. Vector Manufacturing Market in Latin America for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

39. SURVEY ANALYSIS

39.1. Chapter Overview
39.2. Analysis by Seniority Level of Respondents
39.3. Analysis by Type of Manufacturer
39.4. Analysis by Scale of Operation
39.5. Analysis by Type of Vector Manufactured

40. CONCLUDING REMARKS

41. EXECUTIVE INSIGHTS

42. APPENDIX I: TABULATED DATA

43. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

簡介目錄圖表

List of Tables

Table 6.1 Key Features of Viral Vectors
Table 6.2 Key Features of Small-scale Cell Culture Systems
Table 7.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 7.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Vector Manufacturing Facility, Type of Manufacturer and Scale of Operation
Table 7.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Vector Manufactured
Table 7.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 7.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 8.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 8.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facility, Type of Manufacturer and Scale of Operation
Table 8.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 8.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 9.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 9.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Operation
Table 9.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 9.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 10.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 12.1 Viral Vectors and Plasmid DNA Production in North America: List of Profiled Companies
Table 12.2 Advanced BioScience Laboratories: Company Snapshot
Table 12.3 Advanced BioScience Laboratories: Vector Manufacturing Related Capabilities
Table 12.4 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 12.5 Catalent Biologics: Company Snapshot
Table 12.6 Catalent Biologics: Vector Manufacturing Related Capabilities
Table 12.7 Catalent Biologics: Recent Developments and Future Outlook
Table 12.8 Charles River Laboratories: Company Snapshot
Table 12.9 Charles River Laboratories: Vector Manufacturing Related Capabilities
Table 12.10 Charles River Laboratories: Recent Developments and Future Outlook
Table 12.11 Thermo Fisher Scientific: Company Snapshot
Table 12.12 Thermo Fisher Scientific: Vector Manufacturing Related Capabilities
Table 12.13 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 12.14 VectorBuilder: Company Snapshot
Table 12.15 VectorBuilder: Vector Manufacturing Related Capabilities
Table 12.16 VectorBuilder: Recent Developments and Future Outlook
Table 12.17 AGC Biologics: Company Snapshot
Table 12.18 AGC Biologics: Vector Manufacturing Related Capabilities
Table 12.19 Aldevron: Company Snapshot
Table 12.20 Aldevron: Vector Manufacturing Related Capabilities
Table 12.21 Matica Biotechnology: Company Snapshot
Table 12.22 Matica Biotechnology: Vector Manufacturing Related Capabilities
Table 12.23 Resilience: Company Snapshot
Table 12.24 Resilience: Vector Manufacturing Related Capabilities
Table 13.1 Viral Vectors and Plasmid DNA Production in Europe: List of Profiled Companies
Table 13.2 Lonza: Company Snapshot
Table 13.3 Lonza: Vector Manufacturing Related Capabilities
Table 13.4 Lonza: Recent Developments and Future Outlook
Table 13.5 Touchlight: Company Snapshot
Table 13.6 Touchlight: Vector Manufacturing Related Capabilities
Table 13.7 Touchlight: Recent Developments and Future Outlook
Table 13.8 BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech): Company Snapshot
Table 13.8 BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech): Vector Manufacturing Related Capabilities
Table 13.9 Biovian: Company Snapshot
Table 13.10 Biovian: Vector Manufacturing Related Capabilities
Table 13.11 Celonic: Company Snapshot
Table 13.12 Celonic: Vector Manufacturing Related Capabilities
Table 13.13 Centre for Process Innovation: Company Snapshot
Table 13.14 Centre for Process Innovation: Vector Manufacturing Related Capabilities
Table 13.15 CEVEC Pharmaceuticals: Company Snapshot
Table 13.16 CEVEC Pharmaceuticals: Vector Manufacturing Related Capabilities
Table 13.17 NorthX Biologics: Company Snapshot
Table 13.18 NorthX Biologics: Vector Manufacturing Related Capabilities
Table 13.19 Novartis: Company Snapshot
Table 13.20 Novartis: Vector Manufacturing Related Capabilities
Table 13.21 Oxford BioMedica: Company Snapshot
Table 13.22 Oxford BioMedica: Vector Manufacturing Related Capabilities
Table 13.23 Sanofi: Company Snapshot
Table 13.24 Sanofi: Vector Manufacturing Related Capabilities
Table 14.1 Viral Vectors and Plasmid DNA Production in Asia-Pacific: List of

Profiled Companies

Table 14.2 CoJourney: Company Snapshot
Table 14.3 CoJourney: Vector Manufacturing Related Capabilities
Table 14.4 CoJourney: Recent Developments and Future Outlook
Table 14.5 Esco Aster: Company Snapshot
Table 14.6 Esco Aster: Vector Manufacturing Related Capabilities
Table 14.7 Esco Aster: Recent Developments and Future Outlook
Table 14.8 Wuxi AppTec: Company Snapshot
Table 14.9 Wuxi AppTec: Vector Manufacturing Related Capabilities
Table 14.10 Wuxi AppTec: Recent Developments and Future Outlook
Table 14.11 Altruist Biotechnology: Company Snapshot
Table 14.12 Altruist Biotechnology: Vector Manufacturing Related Capabilities
Table 14.13 Jiangsu Puxin Biopharmaceutical: Company Snapshot
Table 14.14 Jiangsu Puxin Biopharmaceutical: Vector Manufacturing Related Capabilities
Table 14.15 Nikon CeLL innovation: Company Snapshot
Table 14.16 Nikon CeLL innovation: Vector Manufacturing Related Capabilities
Table 16.1 Vector and Gene Therapy Manufacturing: List of Partnerships
Table 16.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships
Table 17.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions
Table 17.2 Vector and Gene Therapy Manufacturing: Information on Type of Manufacturing Facility
Table 17.3 Vector and Gene Therapy Manufacturing: Information on Scale of Operation, Type of Vector Manufactured and Application Area
Table 18.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 18.2 AAV Vector-based Therapy Developers: Likely Partners
Table 18.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 18.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 18.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 18.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 18.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 18.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 18.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 18.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 18.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 18.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 18.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 18.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 18.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 18.16 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 18.17 Other Viral Vector-based Therapy Developers: Likely Partners
Table 18.18 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 18.19 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 21.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions /Primary Research
Table 21.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 21.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 23.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 23.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 23.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 23.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 24.1. Global Annual Demand for Viral Vectors Manufacturing
Table 24.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), Till 2035
Table 24.3 Global Viral Vector Manufacturing Annual Supply (Scenario 2), Till 2035
Table 24.4 Global Viral Vector Manufacturing Annual Supply (Scenario 3), Till 2035
Table 24.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-based Cell and Gene Therapies)
Table 24.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 24.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), Till 2035
Table 24.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), Til 2035
Table 24.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 38.1 Survey Responses: Information on Participating Companies / Organizations
Table 38.2 Survey Responses: Information on Seniority Level of Respondents
Table 38.3 Survey Responses: Information on Type of Vector
Table 38.4 Survey Responses: Information on Scale of Operation
Table 38.5 Survey Responses: Information on Availability of Vector Stabilization Technology
Table 38.6 Survey Responses: Information on Type of Manufacturer (In-house Production versus Contract Services)
Table 40.1 HALIX: Key Highlights
Table 40.2 Batavia Biosciences: Key Highlights
Table 40.3 CEVEC Pharmaceuticals: Key Highlights
Table 40.4 Delphi Genetics: Key Highlights
Table 40.5 Clean Cells: Key Highlights
Table 40.6 Novasep: Key Highlights
Table 40.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 40.8 Massachusetts General Hospital: Key Highlights
Table 40.9 University of Nantes: Key Highlights
Table 40.10 CJ PARTNERS: Key Highlights
Table 40.11 ACGT: Key Highlights
Table 40.12 Polypus Transfection: Key Highlights
Table 40.13 Richter-Helm BioLogics: Key Highlights
Table 40.14 Plasmid Factory: Key Highlights
Table 40.15 Waisman Biomanufacturing: Key Highlights
Table 40.16 EFS-West Biotherapy: Key Highlights
Table 40.17 GEG Tech: Key Highlights
Table 40.18 ViveBiotech: Key Highlights
Table 40.19 Independent Consultant: Key Highlights
Table 41.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 41.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 41.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 41.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 41.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Table 41.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 41.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 41.10Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Table 41.11Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 41.12Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Table 41.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 41.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.15Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.16Plasmid DNA and Gene Therapy Manufacturers (Industry Players) Distribution by Location of Headquarters (Region)
Table 41.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 41.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 41.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 41.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 41.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Table 41.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 41.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 41.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Table 41.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Table 41.12 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Viral Vector Manufactured
Table 41.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 41.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 41.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 41.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Table 41.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 41.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Region)
Table 41.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Country)
Table 41.22 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 41.23 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 41.24 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 41.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Year of Establishment
Table 41.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Region)
Table 41.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Country)
Table 41.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer
Table 41.29 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Table 41.30 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 41.31 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Table 41.32 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 41.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 41.34 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 41.35 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Table 41.36 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector
Table 41.37 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 41.38 Most Active Players: Distribution by Number of Technologies
Table 41.39 Catalent Biologics: Annual Revenues
Table 41.40 Charles River Laboratories: Annual Revenues
Table 41.41 Thermo Fisher Scientific: Annual Revenues
Table 41.42 Lonza: Annual Revenues
Table 41.43 Wuxi AppTec: Annual Revenues
Table 41.44 Partnerships and Collaborations: Cumulative Year-wise Trend, Till 2025
Table 41.45 Partnerships and Collaborations: Distribution by Type of Partnership
Table 41.46 Partnerships and Collaborations: Distribution by Scale of Operation
Table 41.47 Partnerships and Collaborations: Distribution by Type of Vector Manufactured
Table 41.48 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 41.49 Partnerships and Collaborations: Distribution by Application Area
Table 41.50 Most Active Players: Distribution by Number of Partnerships
Table 41.51 Partnerships and Collaborations: Local and International Agreements
Table 41.52 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 41.53 Recent Expansions: Cumulative Year-wise Trend, Till 2025
Table 41.54 Recent Expansions: Distribution by Type of Expansion
Table 41.55 Recent Expansions: Distribution by Year and Type of Expansion
Table 41.56 Most Active Players: Distribution by Number of Expansions
Table 41.57 Most Active Players: Distribution by Amount Invested
Table 41.58 Recent Expansions: Distribution by Type of Manufacturing Facility
Table 41.59 Recent Expansions: Distribution by Scale of Operation
Table 41.60 Recent Expansions: Distribution by Type of Vector Manufactured
Table 41.61 Recent Expansions: Distribution by Application Area
Table 41.62 Recent Expansions: Intercontinental and Intracontinental Expansions
Table 41.63 Recent Expansions: Distribution by Location of Expansion
Table 41.64 Viral Vector and Plasmid DNA Manufacturers: Distribution by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Table 41.65 Viral Vector and Plasmid DNA Manufacturers: Distribution by Type of Vector Manufactured and Company Size
Table 41.66 Viral Vector and Plasmid DNA Manufacturers Contract Manufacturing Organizations: Distribution by Geography
Table 41.67 Viral Vector and Plasmid DNA Manufacturers In-House Manufacturers: Distribution by Geography
Table 41.68 Viral Vector and Plasmid DNA Manufacturers In-House and Contract Manufacturing Organizations: Distribution by Geography
Table 41.69 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facility
Table 41.70 Adenoviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.71 Lentiviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.72 Retroviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.73 Plasmid DNA Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.74 Global Installed Viral Vectors Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Table 41.75 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Table 41.76 Global Installed Viral Vector and Plasmid DNA Manufacturing

Capacity (in Liters): Distribution by Type of Vector Manufactured

Table 41.77 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Company Size
Table 41.78 Global Installed Viral Vector Manufacturing Capacity: Distribution by

Range of Installed Capacity (in Liters)

Table 41.79 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Table 41.80 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Table 41.81 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Table 41.82 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
Table 41.83 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 41.84 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Table 41.85 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Table 41.86 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Table 41.87 Global Demand for Viral Vector and Plasmid DNA (Thousand Patients), 2023-2035
Table 41.88 Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients), 2023-2035
Table 41.89 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Table 41.90 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Table 41.91 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Table 41.92 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Table 41.93 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients), 2023-2035
Table 41.94 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Table 41.95 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Table 41.96 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Table 41.97 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Table 41.98 Global Vector Manufacturing Market, Historical Trends (Since 2025)

(USD Million)

Table 41.99 Global Vector Manufacturing Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.100 Vector Manufacturing Market for Preclinical Scale, Historical Trends (:

Since 2021) (USD Million)

Table 41.101 Vector Manufacturing Market for Preclinical Scale, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.102 Vector Manufacturing Market for Clinical Scale, Historical Trends (Since 2021) (USD Million)
Table 41.103 Vector Manufacturing Market for Clinical Scale, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.104 Vector Manufacturing Market for Commercial Scale, Historical Trends (Since 2021) (USD Million)
Table 41.105 Vector Manufacturing Market for Commercial Scale, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.106 Vector Manufacturing Market for AAV Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.107 Vector Manufacturing Market for AAV Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.108 Vector Manufacturing Market for Adenoviral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.109 Vector Manufacturing Market for Adenoviral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.110 Vector Manufacturing Market for Lentiviral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.111 Vector Manufacturing Market for Lentiviral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.112 Vector Manufacturing Market for Retroviral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.113 Vector Manufacturing Market for Retroviral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.114 Vector Manufacturing Market for Non Viral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.115 Vector Manufacturing Market for Non Viral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.116 Vector Manufacturing Market for Other Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.117 Vector Manufacturing Market for Other Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.118 Vector Manufacturing Market for Cell Therapy, Historical Trends (Since 2021) (USD Million)
Table 41.119 Vector Manufacturing Market for Cell Therapy, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.120 Vector Manufacturing Market for Gene Therapy, Historical Trends (Since 2021) (USD Million)
Table 41.121 Vector Manufacturing Market for Gene Therapy, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.122 Vector Manufacturing Market for Vaccines, Historical Trends (Since

2021) (USD Million)

Table 41.123 Vector Manufacturing Market for Vaccines, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.124 Vector Manufacturing Market for Oncological Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.125 Vector Manufacturing Market for Oncological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.126 Vector Manufacturing Market for Rare Diseases, Historical Trends (Since 2021) (USD Million)
Table 41.127 Vector Manufacturing Market for Rare Diseases, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.128 Vector Manufacturing Market for Immunological Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.129 Vector Manufacturing Market for Immunological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.130 Vector Manufacturing Market for Neurological Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.131 Vector Manufacturing Market for Neurological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.132 Vector Manufacturing Market for Sensory Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.133 Vector Manufacturing Market for Sensory Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.134 Vector Manufacturing Market for Metabolic Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.135 Vector Manufacturing Market for Metabolic Disorders, Forecasted

Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 41.136 Vector Manufacturing Market for Blood Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.137 Vector Manufacturing Market for Blood Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.138 Vector Manufacturing Market for Musculoskeletal Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.139 Vector Manufacturing Market for Musculoskeletal Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.140 Vector Manufacturing Market for Infectious Diseases, Historical Trends (Since 2021) (USD Million)
Table 41.141 Vector Manufacturing Market for Infectious Diseases, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.142 Vector Manufacturing Market for Ophthalmic Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.143 Vector Manufacturing Market for Ophthalmic Disorders, Forecasted

Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 41.144 Vector Manufacturing Market for Autoimmune Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.145 Vector Manufacturing Market for Other Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.146 Vector Manufacturing Market for Other Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.147 Vector Manufacturing Market for In-house Manufacturers, Historical Trends (Since 2021) (USD Million)
Table 41.148 Vector Manufacturing Market for In-house Manufacturers, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.149 Vector Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (Since 2021) (USD Million)
Table 41.150 Vector Manufacturing Market for Contract Manufacturing Organizations, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.151 Vector Manufacturing Market in North America, Historical Trend (Since 2021) (USD Million)
Table 41.152 Vector Manufacturing Market in North America, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.153 Vector Manufacturing Market in Europe, Historical Trend (Since 2021) (USD Million)
Table 41.154 Vector Manufacturing Market in Europe, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.155 Vector Manufacturing Market in Asia-Pacific, Historical Trend (Since 2021) (USD Million)
Table 41.156 Vector Manufacturing Market in Asia-Pacific, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.157 Vector Manufacturing Market in Middle East and North Africa, Historical Trend (Since 2021) (USD Million)
Table 41.158 Vector Manufacturing Market in Middle East and North Africa, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.159 Vector Manufacturing Market in Latin America and Rest of the World, Historical Trend (Since 2021) (USD Million)
Table 41.160 Vector Manufacturing Market in Latin America and Rest of the World, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.161 Survey Analysis: Distribution by Seniority Level of Respondents
Table 41.162 Survey Analysis: Distribution by Type of Manufacturer
Table 41.163 Survey Analysis: Distribution by Scale of Operation
Table 41.164 Survey Analysis: Distribution by Type of Vector Manufactured

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Key Market Segmentation
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 7.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 7.2 Vector Manufacturing Operations: Types of Manufacturers
Figure 7.3 Viral Vectors: Manufacturing Process
Figure 7.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 7.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 7.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Figure 7.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Figure 7.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 7.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Figure 7.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Figure 7.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 7.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 7.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Figure 7.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Figure 7.12 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Viral Vector Manufactured
Figure 7.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 8.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 8.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 8.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Figure 8.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Figure 8.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 8.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 8.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Region)
Figure 8.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Country)
Figure 8.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 8.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 8.11 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 9.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Year of Establishment
Figure 9.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Region)
Figure 9.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Country)
Figure 9.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer
Figure 9.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Figure 9.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 9.7 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Figure 9.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 10.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 10.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 10.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Figure 10.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector
Figure 10.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 10.6 Most Active Players: Distribution by Number of Technologies
Figure 11.1 Company Competitiveness Analysis: Viral Vector Manufacturers

based in North America

Figure 11.2 Company Competitiveness Analysis: Viral Vector Manufacturers based

In Europe

Figure 11.3 Company Competitiveness Analysis: Viral Vector Manufacturers based

In Asia-Pacific

Figure 11.4 Company Competitiveness Analysis: Plasmid DNA Manufactures based in North America
Figure 11.5 Company Competitiveness Analysis: Plasmid DNA Manufactures based in Europe
Figure 11.6 Company Competitiveness Analysis: Plasmid DNA Manufactures based in Asia-Pacific
Figure 12.1 Catalent Biologics: Annual Revenues
Figure 12.2 Charles River Laboratories: Annual Revenues
Figure 12.3 Thermo Fisher Scientific: Annual Revenues
Figure 13.1 Lonza: Annual Revenues
Figure 14.1 Wuxi AppTec: Annual Revenues
Figure 15.1 Porter's Five Forces
Figure 15.2 Porter's Five Forces: Harvey Ball Analysis
Figure 16.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Till 2025
Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 16.4 Partnerships and Collaborations: Distribution by Type of Vector Manufactured
Figure 16.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 16.6 Partnerships and Collaborations: Distribution by Application Area
Figure 16.7 Most Active Players: Distribution by Number of Partnerships
Figure 16.8 Partnerships and Collaborations: Local and International Agreements
Figure 16.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, Till 2025
Figure 17.2 Recent Expansions: Distribution by Type of Expansion
Figure 17.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 17.4 Most Active Players: Distribution by Number of Expansions
Figure 17.5 Most Active Players: Distribution by Amount Invested
Figure 17.6Recent Expansions: Distribution by Type of Manufacturing Facility
Figure 17.7 Recent Expansions: Distribution by Scale of Operation
Figure 17.8 Recent Expansions: Distribution by Type of Vector Manufactured
Figure 17.9 Recent Expansions: Distribution by Application Area
Figure 17.10 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 17.11 Recent Expansions: Distribution by Location of Expansion
Figure 20.1 Vector and Gene Therapy Manufacturers: Distribution by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Figure 20.2 Vector and Gene Therapy Manufacturers: Distribution by Type of

Vector Manufactured and Company Size

Figure 20.3 Vector and Gene Therapy Contract Manufacturing Organizations: Distribution by Geography
Figure 20.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Geography
Figure 20.5 Vector and Gene Therapy In-House and Contract Manufacturing Organizations: Distribution by Geography
Figure 20.6 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 20.7 Adenoviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 20.8 Lentiviral Vector Manufacturers: Distribution by Location of

Headquarters and Scale of Operation

Figure 20.9 Retroviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 20.10 Plasmid DNA Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 21.1 Viral Vector and Plasmid DNA based Therapies Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 22.1 Outsourcing: Go / No-Go Framework
Figure 22.2 Outsourcing: Go / No-Go Framework Methodology
Figure 22.3 Outsourcing: Go / No-Go Framework for Cell and Gene Therapy Developers
Figure 22.4 Outsourcing: Go / No-Go Framework for Small Companies
Figure 22.5 Outsourcing: Go / No-Go Framework for Mid-sized Companies
Figure 22.6 Outsourcing: Go / No-Go Framework for Large Companies
Figure 23.1 Global Installed Viral Vectors Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Figure 23.2 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Figure 23.3 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Type of Vector Manufactured
Figure 23.4 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Company Size
Figure 23.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 23.6 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Figure 23.7 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Figure 23.8 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Figure 23.9 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
Figure 23.10Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 23.11Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Figure 23.12Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Figure 23.13Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Figure 24.1 Global Demand for Viral Vector and Plasmid DNA (Thousand Patients), Till 2035
Figure 24.2 Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients), Till 2035
Figure 24.3 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Figure 24.4 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Figure 24.5 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Figure 24.6 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Figure 24.7 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients), Till 2035
Figure 24.8 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Figure 24.9 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Figure 24.10Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Figure 24.11Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Figure 24.12Global Vector Manufacturing: Demand and Supply Analysis, Till 2035
Figure 25.1 Market Drivers
Figure 25.2 Market Restraints
Figure 25.3 Market Opportunities
Figure 25.4 Market Challenges
Figure 26.1 Global Vector Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.2 Global Vector Manufacturing Market, Forecasted Estimates (Till 2035), Conservative Scenario (USD Million)
Figure 26.3 Global Vector Manufacturing Market, Forecasted Estimates (Till 2035), Optimistic Scenario (USD Million)
Figure 27.1 Vector Manufacturing Market: Distribution by Scale of Operation
Figure 27.2 Vector Manufacturing Market for Preclinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.3 Vector Manufacturing Market for Clinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.4 Vector Manufacturing Market for Commercial Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.1 Vector Manufacturing Market: Distribution by Type of Vector
Figure 28.2 Vector Manufacturing Market for AAV Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.3 Vector Manufacturing Market for Adenoviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.4 Vector Manufacturing Market for Lentiviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.5 Vector Manufacturing Market for Retroviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.6 Vector Manufacturing Market for Non Viral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.6 Vector Manufacturing Market for Other Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.1 Vector Manufacturing Market: Distribution by Application Area
Figure 29.2 Vector Manufacturing Market for Cell Therapy Manufacturing: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.3 Vector Manufacturing Market for Gene Therapy Manufacturing: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.4 Vector Manufacturing Market for Vaccines: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.1 Vector Manufacturing Market: Distribution by Type of Therapeutic Area
Figure 30.2 Vector Manufacturing Market for Oncological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.3 Vector Manufacturing Market for Rare Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.4 Vector Manufacturing Market for Immunological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.5 Vector Manufacturing Market for Neurological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.6 Vector Manufacturing Market for Sensory Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.7 Vector Manufacturing Market for Metabolic Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.8 Vector Manufacturing Market for Blood Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.9 Vector Manufacturing Market for Musculoskeletal Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.10 Vector Manufacturing Market for Infectious Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.11 Vector Manufacturing Market for Ophthalmic Disorders: Historical

Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)

Figure 30.12 Vector Manufacturing Market for Autoimmune Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.13 Vector Manufacturing Market for Other Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 31.1 Vector Manufacturing Market: Distribution by Type of Manufacturer
Figure 31.2 Vector Manufacturing Market for In-house Manufacturers: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 31.3 Vector Manufacturing Market for Contract Manufacturing Organizations: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.1 Vector Manufacturing Market: Distribution by Geography
Figure 32.2 Vector Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.3 Vector Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.4 Vector Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.5 Vector Manufacturing Market in Middle East and North Africa: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.5 Vector Manufacturing Market in Latin America and Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 38.1 Survey Analysis: Distribution by Type of Organization
Figure 38.2 Survey Analysis: Distribution by Location of Headquarters
Figure 38.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 38.4 Survey Analysis: Distribution by Type of Manufacturer
Figure 38.5 Survey Analysis: Distribution by Scale of Operation
Figure 38.6 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 39.1 Conclusion: Market Landscape
Figure 39.2 Conclusion: Market Trends
Figure 39.3 Conclusion: Market Forecast and Opportunity Analysis

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

病毒載體和質體DNA 製造市場按產品類型、服務類型、工作流程階段、生產平台、生物製程模式、來源、應用、最終用戶和疾病領域分類 - 全球預測 2025-2030

病毒載體和質粒 DNA 製造市場－全球產業規模、佔有率、趨勢、機會和預測，按產品類型、應用、地區和競爭情況細分，2020-2030 年

表達載體市場 - 全球產業規模、佔有率、趨勢、機會和預測，按宿主類型、應用、最終用戶、地區和競爭細分，2020-2030F

表達載體市場：按產品類型、應用、最終用戶、交付方式分類 - 2025-2030 年全球預測

病毒載體和質粒 DNA 製造市場，按載體類型、工作流程、應用、最終用途、治療領域、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

病毒載體和質粒 DNA 製造市場，按載體類型、工作流程、疾病、應用、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

病毒載體/質體DNA 製造市場規模、佔有率和趨勢分析報告：按載體類型、工作流程、應用、最終用途、疾病、地區和細分市場進行預測，2024-2030 年

FAQ

病毒載體及質粒DNA生產市場（第七版）－產業趨勢及全球預測（至2035年）－依企業規模、載體、應用、治療領域、製造商及地區劃分

Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Scale of Operation, Vector Manufactured, Application Area, Therapeutic Area, Manufacturer and Geographical Regions

病毒載體和質粒DNA生產市場的主要參與者

目錄

第一章：引言

第二章：研究方法

第三章：市場動態

第四章：宏觀經濟指標

第五章：摘要整理

第六章：引言

第七章 病毒載體製造商（產業參與者）：市場概況

第八章 質粒DNA製造商（產業參與者）：市場概況

第九章 病毒載體與質粒DNA製造商（非產業參與者）：市場概況

第十章 載具製造技術展望

第11章 競爭分析

第12章 北美載體生產商

第11章第 13 章：歐洲載體生產商

第 14 章：亞太地區載體生產商

第 15 章：亞太地區載體生產商

第十六章 波特五力分析

第十七章：夥伴關係與合作

第十八章：近期擴張

章節第 19 章：策略夥伴分析

第 20 章：新興載體

第 21 章：主要的洞察

第 22 章：成本分析

第 23 章：外包：可行/不可行架構

第 24 章：產能分析

第 25 章：需求分析

第26章 市場影響分析：驅動因素、限制因素、機會與挑戰

第27章 全球載具製造市場

第28章 載體製造市場（依企業規模劃分）

第29章 載體製造市場（依載體類型劃分）

第30章 載體製造市場（依應用領域劃分）

第31章 載體製造市場（依治療領域劃分）

第32章 載體製造市場（依製造商劃分）

第33章 載體製造市場（依地區劃分）

章節34. 市場機會分析：北美

第35章：市場機會分析：歐洲

第36章：市場機會分析：亞太地區

第37章：市場機會分析：中東與北非

第38章：市場機會分析：拉丁美洲

第39章：研究分析

第40章：結論

第41章：高階主管見解

第42章：附錄一：表格資料

第43章：公司與組織清單

Primary Research Overview

Example Players in the Viral Vector and Plasmid DNA Manufacturing Market

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. VIRAL VECTOR MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

8. PLASMID DNA MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

9. VIRAL VECTOR AND PLASMID DNA MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

10. VECTOR MANUFACTURING TECHNOLOGIES LANDSCAPE

11. COMPANY COOMPETITIVENESS ANALYSIS

12. VECTOR MANUFACTURERS BASED IN NORTH AMERICA

13. VECTOR MANUFACTURERS BASED IN EUROPE

14. VECTOR MANUFACTURERS BASED IN ASIA-PACIFIC

15. VECTOR MANUFACTURERS IN ASIA-PACIFIC

16. PORTER'S FIVE FORCES ANALYSIS

17. PARTNERSHIPS AND COLLAORATIONS

18. RECENT EXPANSIONS

19. STRATEGIC PARTNER ANAYSIS

20. EMERGING VECTORS

21. KEY INSIGHTS

22. COST PRICE ANALYSIS

23. OUTSOURCING: GO / NO-GO FRAMEWORK

24. CAPACITY ANALYSIS

25. DEMAND ANALYSIS

26. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

27. GLOBAL VECTOR MANUFACTURING MARKET

28. VECTOR MANUFACTURING MARKET, BY SCALE OF OPERATION

29. VECTOR MANUFACTURING MARKET, BY TYPE OF VECTOR MANUFACTURED

30. VECTOR MANUFACTURING MARKET, BY APPLICATION AREA

第七章病毒載體製造商（產業參與者）：市場概況

第八章質粒DNA製造商（產業參與者）：市場概況

第九章病毒載體與質粒DNA製造商（非產業參與者）：市場概況

第十章載具製造技術展望

第11章競爭分析

第12章北美載體生產商

第十六章波特五力分析

第26章市場影響分析：驅動因素、限制因素、機會與挑戰

第27章全球載具製造市場

第28章載體製造市場（依企業規模劃分）

第29章載體製造市場（依載體類型劃分）

第30章載體製造市場（依應用領域劃分）

第31章載體製造市場（依治療領域劃分）

第32章載體製造市場（依製造商劃分）

第33章載體製造市場（依地區劃分）